Loading...
Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease
Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosing interstitial lung diseases (ILDs). We present...
Na minha lista:
| Udgivet i: | ERJ Open Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
European Respiratory Society
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8215331/ https://ncbi.nlm.nih.gov/pubmed/34164554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00805-2020 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|